Resource Library

Data Sheet: GORE Protein Capture Device for Early Clinical Applications, 9.0mL (PROA103)

Data Sheets, United States

The 9.0mL Device (PROA103) GORE Protein Capture Device provides performance advantages over traditional agarose resin columns in late stage discovery, pre-clinical and early clinical applications.

View as PDF (242.9 KB)

Contact Us

Americas

+1 800 294 4673

+1 410 506 1715

Europe

+49 89 4612 3456

+800 4612 3456

All Other Inquiries

+1 800 294 4673

+1 410 506 1715

Contact by email

Chromatography News & Events

Event

Visit GORE at BioProcess International in San Diego

February 27, 2023 - March 2, 2023

Join W. L. Gore & Associates for BioProcess International, the largest BioProcessing event for learning how to accelerate promising biologics, cell & gene therapies towards commercial success.

Press Release

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

Posted December 12, 2022

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the global CDMO’s contract development and manufacturing services. By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes, eliminate column bioburden issues, increase product material yields in the research and development (R&D) stages, and help lower costs for clinical manufacturing.

News

A Partnership To Advance Downstream Purification

Posted December 7, 2022

WL Gore and AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), recently announced a powerful collaboration. The partnership brings the GORE® Protein Capture Devices with Protein A as an integral component in the AGC Biologics’ mAb-based CDMO services. The combined offering from GORE and AGC Biologics is available across the CDMO’s global network.